<H1>Chapter DOI: 10.1208/aapsj070372<br/>Cited-By Count: 1</H1><table border="1" width="30%"><tr><td>Total References</td><td>20</td></tr><tr><td>Springer references</td><td>0</td></tr><tr><td>Non Springer references</td><td>20</td></tr><tr><td>BibStructured Count</td><td width="10%">8</td></tr><tr><td>BibUnstructured Count</td><td width="10%">12</td></tr><tr><td>DOI already available in SpringerLink</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>1</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>1</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>1</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>0</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>1</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibBook</td><td>Grubb PW.<Emphasis Type="Italic">Patents for Ch&#234;micals, Pharmaceuticals and Biotechnology</Emphasis>. London, UK: Oxford University Press.; 1999:273.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR2</td><td>BibBook</td><td>Grubb PW.<Emphasis Type="Italic">Patents for Chemicals, Pharmaceuticals and Biotechnology: Fundamentals of Global Law, Practice and Strategy</Emphasis>. London, UK: Oxford University Press; 1999:345.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Rea</span> <span style='background:#DDDDDD'>TS</span></span></aug>. <span style='background:#FFD9B3'>Burns, Doane, Swecker & Mathis LLP Web site</span>. Methods of Maximizing Exclusivity for Pharmaceutical Products. Available at: <span style='background:#FF3300'>http://www.burnsdoane.com/pubs/real.htm.Accessed</span> September 29, <span style='background:#66FF66'>2004</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Mullin R. Priming the Pipeline.<Emphasis Type="Italic">Chem Eng News</Emphasis>. 2004;82:23&#8211;42.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5</td><td>BibUnstructured</td><td><span style='background:#FFD9B3'>A Convergence of Science and Law</span>. <span style='background:#FFFF49'>National Academy Press Web site</span>. <span style='background:#66FF66'>2001</span>. Available at: <span style='background:#FF3300'>http://www.nap.edu/catalog/10174.html</span>. <span style='background:#FFFF0F'>Accessed September 29, 2004</span>.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.17226/10174>10.17226/10174</a></td><td><b>CrossRef-Web</b></td>
<td>Year, BookTitle</td><td>CrossRef</td></tr><tr><td>CR6</td><td>BibChapter</td><td>Levitt GM. The drugs/biologics approval process. In: Pina KR, Pines WL, eds.<Emphasis Type="Italic">A Practical Guide to Food and Drug Law Regulation</Emphasis>. 2nd ed. Washington, DC: Food and Drug Law Institute; 2002.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR7</td><td>BibBook</td><td>Beers DO.<Emphasis Type="Italic">Generic and Innovator Drugs: A Guide to FDA Approval Requirements</Emphasis>. 5th ed. Frederick, MD: Aspen Publishers 1999:3&#8211;24.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR8</td><td>BibBook</td><td>Pressman D.<Emphasis Type="Italic">Patent It Yourself</Emphasis>, 9th ed. Berkeley, CA: Nolo Press; 2002.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR9</td><td>BibBook</td><td>Merges RP, Menell PS, Lanley MA.<Emphasis Type="Italic">Intellectual Property in the New Technological Age</Emphasis>. Frederick, MD: Aspen Press; 2003:215&#8211;274.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Chisum</span> <span style='background:#DDDDDD'>DS</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Jacobs</span> <span style='background:#DDDDDD'>MA</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Bender</span> <span style='background:#DDDDDD'>M.</span></span></aug> <i>Understanding intellectual Property Law</i>. 1999: <span style='background:#D279FF'>&#167;2&#8211;175</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR11</td><td>BibUnstructured</td><td>Lilly v Barr. 222 F3d 973 (Fed Cir <span style='background:#66FF66'>2000</span>).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR12</td><td>BibUnstructured</td><td>Lilly v Barr. 251 F3d 955 (Fed Cir <span style='background:#66FF66'>2001</span>).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR13</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>In</span> <span style='background:#DDDDDD'>re Omeprazole Patent Litigation</span></span>, <span style='background:#BDBAD6'>222 F Supp 2d 423 (S NY</span></aug> <span style='background:#66FF66'>2002</span>).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14</td><td>BibUnstructured</td><td>In re Omeprazole Patent Litigation, 84 Fed Appx 76 (Fed Cir 2003).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR15</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>Consumers Pay Billions a year Too much for &lt;Superscript&gt;Prilosec&#174;&lt;/Superscript&gt;</span>. <span style='background:#FFFF0F'>Available at: http://www.spancoalition.org/Drugs/drug4.htm.Accessed September 28, 2004</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR16</td><td>BibUnstructured</td><td>In re Buspirone Patent Litigation 185 F Supp 2d 340 (S NY 2002).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>More</span> <span style='background:#DDDDDD'>than</span></span></aug> Heartburn at Stake in December 6 &lt;Superscript&gt;Prilosec&#174;&lt;/Superscript&gt; Trial, According to Stop Patient Abuse Now. Available at: <span style='background:#FF3300'>http://www</span>. spancoalition.org/MediaRelease/mediaadvisory 12.05.01.htm. Accessed September 28, <span style='background:#66FF66'>2004</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR18</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Chan</span> <span style='background:#DDDDDD'>FM</span></span></aug>. <span style='background:#FFD9B3'>Potential Blockbuster Drugs</span>. Available at: <span style='background:#FF3300'>http://ww.forbes.com/2003/10/08/cz-finc-1008sf.html</span>. Accessed September 29, <span style='background:#66FF66'>2004</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR19</td><td>BibBook</td><td>Hughes J, Moore M, Snyder E. Napsterizing Pharmaceuticals: Access, Innovation, and Consumer Welfare, National Bureau of Economic Research Working paper No. 9229. Cambridge, MA. NBER; 2002.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR20</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Eurek</span> <span style='background:#DDDDDD'>SE</span></span></aug> Hatch-Waxman Reform and Accelerated Market Entry of Generic Drugs: Is Faster Necessarily Better? Duke L & Tech Rev. <span style='background:#66FF66'>2003</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>